articleImmunityMar 1, 2022HYBRID OA

Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses

KLKarl L. BantaXXXiaozheng XuASAvantika S. ChitreAAAmelia Au‐YeungCTChikara Takahashi

University of California San Diego · Genesys (United States)

PubMed
Indexed incrossrefpubmed

Abstract

T cell responses, requires blockade of TIGIT and PD-1, providing a mechanistic rationale for combinatorial targeting in the clinic.

Citation impact

344
total citations
FWCI
32.24
Percentile
100%
References
72
Citations per year

Authors

16

Topics & keywords

Topics
Keywords
  • TIGIT
  • Blockade
  • CD28
  • Cancer research
  • Atezolizumab
  • Cytotoxic T cell
  • CD8
  • T cell
No related works found for this paper.